The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham &Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program.
Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials;identify novel trials to be brought to NCTN;prioritize NCTN trials within our clinical trials portfolio;assure timely activation;provid training and mentoring;distribute funding fairly;and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees;2) participation in CIRB;3) executive and committee leadership and membership;4) executive and committee leadership, as well as committee membership;5) serving as affiliated PIs;6) leadership in accrual;and 7) training a new generation to participate in the national clinical trials network enterprise.

Public Health Relevance

NCTN trials will be developed and supported by national experts from DF/PCC. We will conduct those trials with greatest potential value in advancing our knowledge and ability to treat cancer. Importantly, trials will be for both common cancers and rare ones that require support from many centers to have a sufficient subject. The benefit to society could be substantial if trials improve survival and quality of life.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180867-01
Application #
8605646
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-19
Project End
2019-02-28
Budget Start
2014-05-19
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,302,200
Indirect Cost
$527,357
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Roboz, Gail J; Mandrekar, Sumithra J; Desai, Pinkal et al. (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv 2:3608-3617
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718

Showing the most recent 10 out of 174 publications